Immuneering Corporation Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Immuneering Corporation (IMRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $3.68 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-05
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $3.50, a 3.24% increase year-over-year.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.39, a 58.96% decline year-over-year.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $8.26, a 14.49% decline year-over-year.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $9.66, a 38.00% increase year-over-year.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $2.90, a 58.15% decline from fiscal 2024.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $6.93, a 14.44% decline from fiscal 2023.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $8.10, a 19.24% decline from fiscal 2022.
- Immuneering Corporation share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $10.03.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.68 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $3.50 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $2.90 10-K · filed 2026-03-06 | |||
| 2025-09-30 | $2.90 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $2.96 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | $3.39 10-Q · filed 2025-05-05 | |||
| 2024-12-31 | $6.93 10-K · filed 2025-03-20 | |||
| 2024-09-30 | $8.84 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $8.84 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $8.26 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $8.10 10-K · filed 2024-03-01 | |||
| 2023-09-30 | $9.39 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $9.38 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $9.66 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $10.03 10-K · filed 2023-03-06 | |||
| 2022-09-30 | $9.41 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $6.58 10-Q · filed 2022-08-10 | |||
| 2022-03-31 | $7.00 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |